HPI has multiple Abbreviated New Drug Applications (ANDAs) pending FDA approval, with additional products in development. Our primary
strategy is to develop, manufacture and commercialize our own ANDAs. At the same time, in order to offer our customers a varied and
complete dermatological product portfolio, we will also be acquiring or licensing additional products that fulfill our niche.
HPI products will be marketed through national wholesalers and distributors, and direct to major warehousing customers. Our customer
markets include wholesaler multi-source programs, chain drug stores, managed healthcare providers, and institutional and government
healthcare providers.
As a manufacturer and developer with a unique focus - dermatology - we represent a new and powerful choice in an increasingly
consolidating marketplace.
